Wang Y - Search Results

1

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.

Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Yu C, Zhou X, Lin R, Chen Y, Tu S, Huang X, Liu Q. Xuan L, et al. Among authors: wang z, wang y. Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10. Lancet Oncol. 2020. PMID: 32791048 Clinical Trial.

2

Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.

Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y, Han W, Chen H. Huang XJ, et al. Among authors: wang y. J Clin Immunol. 2008 May;28(3):276-83. doi: 10.1007/s10875-007-9166-z. J Clin Immunol. 2008. PMID: 18204965

3

Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study.

Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, Zhang X, Han W, Wang Y, Zhao T, Wang J, Wang J, Han Q, Zhao C, Huang X. Liu K, et al. Among authors: wang j, wang y. Stem Cells Dev. 2011 Oct;20(10):1679-85. doi: 10.1089/scd.2010.0447. Epub 2011 Feb 5. Stem Cells Dev. 2011. PMID: 21142788 Clinical Trial.

4

[The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].

Xu LP, Liu DH, Liu KY, Chen H, Han W, Wang Y, Wang J, Shi HX, Huang XJ. Xu LP, et al. Among authors: wang j, wang y. Zhonghua Nei Ke Za Zhi. 2010 Nov;49(11):955-8. Zhonghua Nei Ke Za Zhi. 2010. PMID: 21211211 Chinese.

5

[A comparative study of different intervention regimens for chronic myelogenous leukemia post allogeneic hematopoietic stem cell transplantation].

Xu LP, Liu DH, Liu KY, Chen H, Han W, Zhang XH, Chen YH, Wang Y, Qin YZ, Huang XJ. Xu LP, et al. Among authors: wang y. Zhonghua Xue Ye Xue Za Zhi. 2010 Nov;31(11):758-62. Zhonghua Xue Ye Xue Za Zhi. 2010. PMID: 21223731 Chinese.

6

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.

Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ. Jiang Q, et al. Among authors: wang y. Blood. 2011 Mar 17;117(11):3032-40. doi: 10.1182/blood-2010-09-308510. Epub 2011 Jan 20. Blood. 2011. PMID: 21252092 Free article. Clinical Trial.

7

Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Shi HX, Han W, Zhan XH, Wang Y, Zhao T, Huang XJ. Chen H, et al. Among authors: wang y. Chin Med J (Engl). 2011 Jan;124(2):246-52. Chin Med J (Engl). 2011. PMID: 21362375 Clinical Trial.

8

Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.

Huang BT, Wang Y, Du QF, Yang J, Yu J, Zeng QC, Xu N, Zhang JF, Xu LL, Luo XJ, Wei YQ, Liu XL. Huang BT, et al. Among authors: wang y. Int J Hematol. 2011 Apr;93(4):474-481. doi: 10.1007/s12185-011-0804-0. Epub 2011 Mar 10. Int J Hematol. 2011. PMID: 21387092

9

The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.

Liu DH, Zhao XS, Chang YJ, Liu YK, Xu LP, Chen H, Han W, Chen YH, Wang Y, Huang XJ. Liu DH, et al. Among authors: wang y. Pediatr Blood Cancer. 2011 Jul 15;57(1):135-41. doi: 10.1002/pbc.23107. Epub 2011 Mar 17. Pediatr Blood Cancer. 2011. PMID: 21416583

10

[Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].

Xu N, Ouyang Z, DU QF, Wang S, Yang J, Wang Y, Liu XL. Xu N, et al. Among authors: wang y, wang s. Zhonghua Xue Ye Xue Za Zhi. 2011 Jan;32(1):25-8. Zhonghua Xue Ye Xue Za Zhi. 2011. PMID: 21429397 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

272,410 results

Search Page